- Report
- November 2023
- 144 Pages
Global
From €2400EUR$2,499USD£2,066GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,034GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
Ambisome is a brand of liposomal amphotericin B, an antifungal drug used to treat a variety of fungal infections. It is used to treat serious fungal infections in patients with weakened immune systems, such as those with HIV/AIDS, cancer, or organ transplants. Ambisome is a polyene antifungal drug, meaning it works by binding to the cell membrane of the fungus and disrupting its structure. It is generally used as a last resort when other antifungal drugs have failed.
Ambisome is part of the larger Infectious Diseases Drugs market, which includes a variety of drugs used to treat bacterial, viral, and fungal infections. These drugs are used to treat a wide range of infections, from common colds to life-threatening illnesses.
Some companies in the Infectious Diseases Drugs market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more